Article
Abbott's UroVysion DNA probe assay has been approved by the FDA for use as an aid in initial diagnosis of bladder cancer in patients with hematuria and suspected of having bladder cancer.
Phase 3 ENLIGHTED trial: Padeliporfin VTP shows promise in low-grade UTUC
Key updates from the AUA/ASRM male infertility guideline amendment
Expert roundtables focus on upper tract urothelial carcinoma
Speaking of Urology: Dr. Winter on the use of vaginal estrogen
Money Matters: Go into 2025 strong with this year-end financial checklist
CMS adjusts reimbursement for diagnostic radiopharmaceuticals